JP2002508338A5 - - Google Patents

Download PDF

Info

Publication number
JP2002508338A5
JP2002508338A5 JP2000538720A JP2000538720A JP2002508338A5 JP 2002508338 A5 JP2002508338 A5 JP 2002508338A5 JP 2000538720 A JP2000538720 A JP 2000538720A JP 2000538720 A JP2000538720 A JP 2000538720A JP 2002508338 A5 JP2002508338 A5 JP 2002508338A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
hiv
composition according
lentivirus
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000538720A
Other languages
Japanese (ja)
Other versions
JP2002508338A (en
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1998/025720 external-priority patent/WO1999030742A1/en
Publication of JP2002508338A publication Critical patent/JP2002508338A/en
Publication of JP2002508338A5 publication Critical patent/JP2002508338A5/ja
Pending legal-status Critical Current

Links

Description

【特許請求の範囲】
【請求項１】 レンチウィルス ベクターを含んで成る、レンチウィルスにより感染された対象を治療するための医薬組成物。
【請求項２】 前記ベクターが、損なわれていない５’LTR （長い末端反復体）を有する請求項１記載の医薬組成物。
【請求項３】 前記レンチウィルスが、ヒト免疫欠損ウィルス（HIV ）である請求項１記載の医薬組成物。
【請求項４】 前記HIV が、HIV −１である請求項３記載の医薬組成物。 [Claims]
1. A pharmaceutical composition for treating a subject infected by a lentivirus, comprising a lentiviral vector.
2. The pharmaceutical composition according to claim 1, wherein the vector has an intact 5 ′ LTR (long terminal repeat).
3. The pharmaceutical composition according to claim 1, wherein the lentivirus is a human immunodeficiency virus (HIV).
4. The pharmaceutical composition according to claim 3, wherein the HIV is HIV-1.

JP2000538720A 1997-12-12 1998-12-11 Therapeutic use of lentiviral vectors Pending JP2002508338A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6957997P 1997-12-12 1997-12-12
US60/069,579 1997-12-12
PCT/US1998/025720 WO1999030742A1 (en) 1997-12-12 1998-12-11 Therapeutic use of lentiviral vectors

Publications (2)

Publication Number Publication Date
JP2002508338A JP2002508338A (en) 2002-03-19
JP2002508338A5 true JP2002508338A5 (en) 2006-01-26

Family

ID=22089926

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000538720A Pending JP2002508338A (en) 1997-12-12 1998-12-11 Therapeutic use of lentiviral vectors

Country Status (6)

Country Link
EP (1) EP1037669A4 (en)
JP (1) JP2002508338A (en)
KR (1) KR20010033062A (en)
AU (1) AU749059B2 (en)
CA (1) CA2314683A1 (en)
WO (1) WO1999030742A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030847A1 (en) 1999-10-22 2001-05-03 Aventis Pasteur Limited Modified gp100 and uses thereof
US6656706B2 (en) 1999-12-23 2003-12-02 The United States Of America As Represented By The Department Of Health And Human Services Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
AU5810201A (en) 2000-05-10 2001-11-20 Aventis Pasteur Immunogenic polypeptides encoded by mage minigenes and uses thereof
US6712612B1 (en) 2000-12-12 2004-03-30 Genecure Llc Safe and stable retroviral helper cell line and related compositions and methods
US20040225077A1 (en) 2002-12-30 2004-11-11 Angiotech International Ag Drug delivery from rapid gelling polymer composition
JP2006524051A (en) 2003-04-24 2006-10-26 フォンダッチォーネ・セントロ・サン・ラファエル・デル・モンテ・タボール Lentiviral vector with bi-directional synthetic promoter and use thereof
US20120040367A1 (en) 2007-10-15 2012-02-16 The University Of Queensland Construct system and uses therefor
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
WO2017096432A1 (en) 2015-12-09 2017-06-15 Admedus Vaccines Pty Ltd Immunomodulating composition for treatment
WO2018018082A1 (en) 2016-07-26 2018-02-01 The Australian National University Immunostimulatory compositions and uses therefor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3325579B2 (en) * 1995-03-16 2002-09-17 久光製薬株式会社 New recombinants
US5650309A (en) * 1995-05-16 1997-07-22 The Regents Of The University Of California Viral vectors
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
DE69626681T2 (en) * 1995-11-28 2004-02-12 The Johns Hopkins University School Of Medicine CONDITIONAL REPLICATIVE VIRAL VECTORS AND THEIR USE.
WO1997020052A1 (en) * 1995-11-28 1997-06-05 Clinical Technologies, Inc. Recombinant hiv and modified packaging cells and method for treating acquired immune deficiency syndrome
JP2000517290A (en) * 1996-02-21 2000-12-26 リスジーウィックス，ジュリアナ Methods and compositions for protective and therapeutic gene immunization
AU723313B2 (en) * 1996-03-05 2000-08-24 Regents Of The University Of California, The Recombinant live feline immunodeficiency virus and proviral DNA vaccines
CA2261987C (en) * 1996-07-22 2008-09-30 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Vectors for inhibiting hiv and tumor growth
JP2001513643A (en) * 1997-03-06 2001-09-04 ウーベルラ、クラウス Vectors and vector systems based on lentivirus
GB9704977D0 (en) * 1997-03-11 1997-04-30 Univ Glasgow FIV vaccine
WO1999004026A2 (en) * 1997-07-18 1999-01-28 Chiron Corporation Lentiviral vectors

Similar Documents

Publication Publication Date Title
EP2267452B8 (en) A soluble complex comprising a retroviral surface glycoprotein
CA2022539A1 (en) Albumin derivatives with therapeutic functions
TR200001553T2 (en) HIV-1 Tat or its derivatives.
WO2001010456A3 (en) Peptides that block viral infectivity and methods of use thereof
ATE264914T1 (en) ANTIVIRAL PROTEINS, DNA CODING THEREOF, AND USE THEREOF
EA200200724A1 (en) VACCINE FOR PREVENTION OR THERAPEUTIC IMMUNIZATION AGAINST THE VIRUS OF HUMAN IMMUNODEFICIENCY (HIV)
CY1112632T1 (en) ASPARTYL PROTECTION Suspensions
JP2002508338A5 (en)
MXPA02007478A (en) Human immunodeficiency virus vaccine.
EP0225066A3 (en) Antigen determinant peptides and a process for the preparation thereof
WO2000061067A3 (en) Anti-hiv 1 vaccine comprising the entire or part of the tat hiv-1 protein
NO940810L (en) Treatment of viral infections
CA2195125A1 (en) Difluorostatone antiviral agents
WO1996001110A3 (en) Anti-hiv triple combination
JP2002523426A5 (en)
WO2000018433A3 (en) Use of antigenic complexes of hiv envelope and hla class i antigens as hiv vaccine
DE69922642D1 (en) VIRAL CHIMERS FROM CAEV AND HIV-1 GENETIC ELEMENTS
RU96116005A (en) STRAIN HOMINIS IMMUNODEFICITI VIRUS (HIV-I) HIV-I / RUSSIA / GM-12-95 (RU1295) SUBTYPE B FOR DIAGNOSTIC AND VACCINE DRUGS
FR2647809B1 (en) OLIGONUCLEOTIDE PRIMERS FOR THE AMPLIFICATION OF THE GENOME OF HIV-1, HIV-2 AND SIV RETROVIRUSES AND THEIR APPLICATIONS TO IN VITRO DIAGNOSIS OF INFECTIONS DUE TO THESE VIRUSES
WO2004041194A3 (en) Inhibition of hiv-1 replication
JP2007515386A5 (en)
FR2652091B1 (en) NUCLEOTIDE SEQUENCES ARISING FROM THE GENOME OF HIV-1, HIV-2 AND SIV RETROVIRUSES, AND THEIR APPLICATIONS IN PARTICULAR FOR THE AMPLIFICATION OF THE GENOMES OF THESE RETROVIRUSES AND FOR THE IN-VITRO DIAGNOSIS OF INFECTIONS DUE TO THESE VIRUSES.
WO1999061011A3 (en) Use of a medicine containing a quantity of tyrothricine for the treatment of viral infections
NO963254L (en) Macrocyclic difluorostatone derivatives useful as antivirals
RU2003116404A (en) STRAIN OF THE WEST HORSE ENCEPHALOMYELITIS VIRUS (WESTERN ENCEPHALOMYELITIS VIRUS-WEE 163-A) STB N 964 FOR PREPARATION OF DIAGNOSTIC AND PREVENTIVE PREPARATIONS